Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.

Digestive diseases and sciences - 1 Sept 2018

Boden Elisa K, Shows Donna M, Chiorean Michael V, Lord James D

Abstract excerpt

BACKGROUND/AIMS: Vedolizumab is an anti-α4β7 monoclonal antibody approved for the treatment of inflammatory bowel disease (IBD). This exploratory study aimed to identify biomarkers associated with vedolizumab response. METHODS: Twenty-six IBD patients (15 with Crohn's, 11 with ulcerative or indeterminate colitis) initiating vedolizumab at a single center between 2014 and 2016 underwent sampling of serum and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Colitis, Ulcerative

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Endoscopy, Gastrointestinal

Share to Gastrointestinal Agents

Share to Integrins

Share to Lymphocyte Subsets

Share to Remission Induction

Share to Washington

Source

Identifiers

PMID: 29372476
DOI: 10.1007/s10620-018-4924-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of Candidate Biomarkers Associated with Response to Vedolizumab in Inflammatory Bowel Disease.PMID 29372476Read ↗

Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.Semantic proximity Read ↗

Multimodal Profiling of Peripheral Blood Identifies Proliferating Circulating Effector CD4+ T Cells as Predictors for Response to Integrin α4β7-Blocking Therapy in Inflammatory Bowel Disease.Semantic proximity Read ↗

Residual homing of α4β7-expressing β1 + PI16 + regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumabSemantic proximity Read ↗

High-dimensional single-cell analysis identifies cellular signatures associated with response to vedolizumab therapy in ulcerative colitisSemantic proximity Read ↗

Single-cell characterization of peripheral blood mononuclear cells from vedolizumab-treated patients with Crohn's disease identifies response-associated differences among the plasmacytoid dendritic cell and classical monocyte populations.Semantic proximity Read ↗

A pilot study to identify blood-based markers associated with response to treatment with Vedolizumab in patients with Inflammatory Bowel DiseaseSemantic proximity Read ↗

Gut-associated lymphoid tissue attrition associates with response to anti-α4β7 therapy in ulcerative colitisSemantic proximity Read ↗

Downregulated Interferon Signalling in T Cells is Associated with Response to Vedolizumab in Inflammatory Bowel DiseaseSemantic proximity Read ↗

High-Throughput Whole-Exome Sequencing and Large-Scale Computational Analysis to Identify the Genetic Biomarkers to Predict the Vedolizumab Response Status in Inflammatory Bowel Disease Patients from Saudi ArabiaSemantic proximity Read ↗

Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.Semantic proximity Read ↗

Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantationSemantic proximity Read ↗

Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.